CD52

Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT

Retrieved on: 
Thursday, May 9, 2024
Biotechnology, Genetics, Health, Cell, Research, Engineering, Patient, Point mutation, Society, Therapy, CD52, Vaccine

Cimeio Therapeutics, a biotechnology company leading the field of epitope shielding, is presenting data for its CD52 program during this week’s Annual Meeting of the American Society of Cell & Gene Therapy (ASGCT) in Baltimore.

Key Points: 
  • Cimeio Therapeutics, a biotechnology company leading the field of epitope shielding, is presenting data for its CD52 program during this week’s Annual Meeting of the American Society of Cell & Gene Therapy (ASGCT) in Baltimore.
  • The abstract is titled “Molecular Shielding of CD52 Retains Expression, Anti-Phagocytic Don’t Eat Me Function and Protects from Alemtuzumab-Mediated Depletion.”
    The study is the first showing that T cells expressing an engineered CD52 can be effectively shielded from Alemtuzumab-mediated depletion, while maintaining the general features of this receptor.
  • Cimeio's research team also showed for the first time that CD52 mediates an anti-phagocytotic ‘Don’t Eat Me’ signal, which is retained by the engineering.
  • “We are excited to explore the full potential of our engineered CD52 receptor in the future.

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024
Urinary tract infection, Patient, Medical Subject Headings, Marketing, Agency, Jaw, INN, Interferon beta-1a, Immune system, Fever, Tears, ATC, Disability, Multiple sclerosis, Kidney, Hypertension, International, Blood, RRMS, Attack, Spinal cord, Disease, Headache, Language, Brain, Myocardial infarction, Eye, Heart, Inflammation, Thyroid, Stroke, Head, Angina, European Medicines Agency, Infection, Coagulopathy, Lymphocyte, HIV, Select, Central nervous system, Human, Safety, Anatomy, Checklist, Sclerosis, IIA, Optic nerve, Neck, Rash, CD52, Medical device

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
Monday, June 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Retrieved on: 
Wednesday, May 31, 2023
Graft-versus-host disease, Antigen, TRAC, Euronext Growth, CD19, Lymphoid leukemia, CD20, Neoplasm, CD52, Bone marrow, CD22, Attention, PDX, CAR, Death, Cancer Immunology Research, Animal, Patient, Risk, Mantle cell lymphoma, Cancer, Research, Vaccine, Cellectis

To address these challenges, Cellectis developed UCART20x22, its first allogeneic dual CAR T-cell product candidate targeting two validated antigens commonly expressed in B-cell malignancies, CD20 and CD22, and whose expression is preserved after CD19 CAR T-cell treatment.

Key Points: 
  • To address these challenges, Cellectis developed UCART20x22, its first allogeneic dual CAR T-cell product candidate targeting two validated antigens commonly expressed in B-cell malignancies, CD20 and CD22, and whose expression is preserved after CD19 CAR T-cell treatment.
  • Moreover, UCART20x22 is developed to be available off-the-shelf and to offer a solution for patients whose T-cells are not functional or for which autologous manufacturing fails.
  • UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house at Cellectis.
  • This article is available on Cancer Immunology Research website by clicking on this link: https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066....

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Retrieved on: 
Thursday, May 11, 2023
Graft-versus-host disease, TRAC, Euronext Growth, Assistance Publique–Hôpitaux de Paris, CD19, European Hematology Association, Relapse, CD52, Cyclophosphamide, FC, Allotransplantation, CAR, Patient, B-ALL, Risk, EHA, Alemtuzumab, FCA, Infrared spectroscopy correlation table, Safety, Vaccine, Pharmaceutical industry, Cellectis

“Cellectis is excited to present updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Key Points: 
  • “Cellectis is excited to present updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
  • The data show that UCART22 was well tolerated and clinical responses were achieved.
  • UCART22 continues to have a good safety profile, with no serious treatment emergent adverse events (TEAEs) or DLTs reported.
  • Overall, these data support the safety and preliminary efficacy of UCART22 in a heavily pretreated r/r B-ALL population.

Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Tuesday, May 2, 2023
Graft-versus-host disease, TRAC, Euronext Growth, ASH, Gene, Relapse, Neoplasm, LD, Gene editing, CD52, UCART123, Cyclophosphamide, FC, Allotransplantation, CAR, AML, Patient, Risk, Annual general meeting, Alemtuzumab, Cell, FCA, American Society of Gene and Cell Therapy, Society, Bone marrow, Vaccine, Cellectis

The data show that adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123 cell expansion, which correlated with improved activity.

Key Points: 
  • The data show that adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123 cell expansion, which correlated with improved activity.
  • However, additional physiological and biological barriers imposed by the hostile tumor microenvironment has limited the ability to target solid tumors.
  • This glimpse of success also demonstrated that we need to be able to creatively customize and equip CAR T-cells to target these tumors.
  • By carefully choosing a range of gene and cell engineering approaches, Cellectis can develop CAR T-cells focused on unmet medical needs with a high level of efficiency for gene editing and targeted-integration.

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab

Retrieved on: 
Monday, April 24, 2023
Partnership, Euronext Growth, ASH, ALL, IMP, CD52, NHL, UCART123, CAR, AML, Alemtuzumab, Sanofi, Vaccine, Cellectis

In May 2021, Cellectis entered into partnership and supply agreements with Sanofi regarding alemtuzumab.

Key Points: 
  • In May 2021, Cellectis entered into partnership and supply agreements with Sanofi regarding alemtuzumab.
  • Under the agreements, Sanofi is supplying alemtuzumab to support Cellectis’ clinical trials and the parties agreed to enter into discussions to execute a commercial supply of alemtuzumab under pre-agreed financial conditions.
  • Cellectis is the inventor of the combination of CD52 knockout UCART cells with a lymphodepleting regimen containing an anti-CD52 antibody such as alemtuzumab.
  • The CD52 knockout aims to render UCART product candidates resistant to alemtuzumab as part of the lymphodepleting regimen.

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Retrieved on: 
Thursday, November 10, 2022
CD52, TRAC, GLOBE, Private Securities Litigation Reform Act, YouTube, Forward-looking statement, Manuscript, Euronext Growth, Gene, Technology, U.S. Securities and Exchange Commission, Knockout, Comprehension, CAR, DNA, Annual report, NASDAQ, Gene editing, Cas9, Cancer, Biological engineering, Frontiers Media, Chromosomal translocation, Nasdaq, Patient, Immune system, Social media, Securities & Exchange Commission of Pakistan, Vaccine, Biotechnology, Cellectis

TALE base editors are a recent and very important addition to the gene editing landscape.

Key Points: 
  • TALE base editors are a recent and very important addition to the gene editing landscape.
  • This combination of molecular tools paves the way to simultaneous multiplex gene engineering with more controllable outcomes.
  • This article is available on Frontiers in Bioengineering and Biotechnology website by clicking on this link.
  • Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies.

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
EOE, CD52, GLOBE, Lirentelimab, Private Securities Litigation Reform Act, AK002, EOD, Abstract, B cell, Eosinophilic esophagitis, Immunosuppression, Annual general meeting, Food, Nasdaq, EG, Immunotherapy, Macrophage, Neoplasm, Tams, Eosinophil, Securities Act of 1933, DC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, CD47, Atopic dermatitis, SEC, Ligand, Antibody, Annual report, PD-1, Myelocyte, SITC, Securities Exchange Act of 1934, Allergy, Survival, VAP-1, Safety, Inflammation, Company, Cancer, Gastrointestinal tract, Poster, Cell, Skin, Patient, Justice and Security Act 2013, CD24, Society, Vaccine, Medical imaging, Pharmaceutical industry

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. The poster presentation highlights pre-clinical data supporting Siglec-10 as a promising myeloid target for enhancing anti-tumor immunity in solid tumors.

Key Points: 
  • The poster presentation highlights pre-clinical data supporting Siglec-10 as a promising myeloid target for enhancing anti-tumor immunity in solid tumors.
  • Restoring myeloid cell function has the potential to increase anti-tumor immunity by activating both innate and adaptive immune cells.
  • AK007 is a humanized Siglec-10 antagonist antibody designed to block Siglec-10 interaction with all known ligands (CD24, CD52, and VAP-1).
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Retrieved on: 
Thursday, November 3, 2022
Patient, LD, NEW, Company, Neoplasm, Private Securities Litigation Reform Act, MM, Vrije Universiteit Amsterdam, Alemtuzumab, 2021 Essex County Council election, PM, Society, Acute leukemia, U.S. Securities and Exchange Commission, CD52, Cyclophosphamide, GLOBE, CAR, FC, Population, Adult, TRAC, ASH, Degenerative disease, Relapse, Allotransplantation, Acute myeloid leukemia, Graft-versus-host disease, Nasdaq, Investigational New Drug, YouTube, Annual report, Social media, Clinical trial, Euronext Growth, Hodgkin lymphoma, Multiple myeloma, FCA, Forward-looking statement, Risk, NASDAQ, Immune system, Disease, Gene editing, Technology, Securities & Exchange Commission of Pakistan, AML, Time, UCART123, Cancer, Department, Pharmaceutical industry, Vaccine, Cellectis, Hematology

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the release of two abstracts, which were accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting taking place from December 10 to 13, 2022.

Key Points: 
  • The Company will present, in an oral session on December 12, preliminary clinical data from its AMELI-01 clinical trial (evaluating UCART123) in patients with relapsed/refractory acute myeloid leukemia (r/r AML).
  • Amsterdam University Medical Center (location VUmc), in collaboration with Cellectis, will also present, in a poster session on December 10, preclinical data supporting anti-tumor activity for Cellectis UCARTCS1 product candidate, which is being evaluated in clinical trial, MELANI-01, for patients with relapsed/refractory multiple myeloma (r/r MM).
  • Cellectis is excited to share preliminary clinical data from our AMELI-01 clinical trial, evaluating UCART123 in patients with relapsed and/or refractory acute myeloid leukemia.
  • The potential impact of previous therapy and tumor characteristics on the in vitro efficacy of UCARTCS1 was also investigated.